Swedish Orphan Biovitrum AB (publ) Asset Resilience Ratio

Latest as of December 2025: 1.54%

Swedish Orphan Biovitrum AB (publ) asset resilience ratio. Swedish Orphan Biovitrum AB (publ) (SOBI) has an Asset Resilience Ratio of 1.54% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SOBI liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets

Skr1.04 Billion

≈ $112.03 Million USD Cash + Short-term Investments

Total Assets

Skr67.43 Billion

≈ $7.26 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Swedish Orphan Biovitrum AB (publ) (2006–2025)

Asset resilience ratio of Swedish Orphan Biovitrum AB (publ) from 2006 to 2025. This chart shows how Swedish Orphan Biovitrum AB (publ)'s Asset Resilience Ratio has changed over time. See Swedish Orphan Biovitrum AB (publ) free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Swedish Orphan Biovitrum AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SOBI total assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr1.04 Billion	1.54%
Short-term Investments	Skr0.00	0%
Total Liquid Assets	Skr1.04 Billion	1.54%

Asset Resilience Insights

Limited Liquidity: Swedish Orphan Biovitrum AB (publ) maintains only 1.54% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Swedish Orphan Biovitrum AB (publ) Industry Peers by Asset Resilience Ratio

Compare Swedish Orphan Biovitrum AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Curaleaf Holdings Inc. TO:CURA	Drug Manufacturers - Specialty & Generic	3.73%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%
Zhejiang Medicine Co Ltd SHG:600216	Drug Manufacturers - Specialty & Generic	1.85%
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	Drug Manufacturers - Specialty & Generic	0.40%
Dezhan HealthCare Co Ltd SHE:000813	Drug Manufacturers - Specialty & Generic	0.09%
Chongqing Pharscin Pharmaceutical Co Ltd SHE:002907	Drug Manufacturers - Specialty & Generic	14.54%

Swedish Orphan Biovitrum AB (publ) Asset Resilience Ratio by Year (2006–2025)

Swedish Orphan Biovitrum AB (publ) asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Swedish Orphan Biovitrum AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.54%	Skr1.04 Billion ≈ $112.03 Million	Skr67.43 Billion ≈ $7.26 Billion	-0.14pp
2024-12-31	1.68%	Skr1.27 Billion ≈ $136.67 Million	Skr75.44 Billion ≈ $8.12 Billion	+0.46pp
2023-12-31	1.22%	Skr904.00 Million ≈ $97.28 Million	Skr74.03 Billion ≈ $7.97 Billion	-1.35pp
2022-12-31	2.58%	Skr1.35 Billion ≈ $145.50 Million	Skr52.50 Billion ≈ $5.65 Billion	+0.45pp
2021-12-31	2.13%	Skr1.04 Billion ≈ $111.49 Million	Skr48.66 Billion ≈ $5.24 Billion	+1.29pp
2020-12-31	0.84%	Skr404.00 Million ≈ $43.48 Million	Skr48.28 Billion ≈ $5.20 Billion	-0.78pp
2019-12-31	1.61%	Skr737.00 Million ≈ $79.31 Million	Skr45.66 Billion ≈ $4.91 Billion	-15.84pp
2018-12-31	17.45%	Skr3.00 Billion ≈ $322.71 Million	Skr17.18 Billion ≈ $1.85 Billion	+3.89pp
2017-12-31	13.56%	Skr1.48 Billion ≈ $159.11 Million	Skr10.90 Billion ≈ $1.17 Billion	+5.68pp
2016-12-31	7.88%	Skr786.00 Million ≈ $84.59 Million	Skr9.97 Billion ≈ $1.07 Billion	+6.16pp
2009-12-31	1.72%	Skr48.36 Million ≈ $5.20 Million	Skr2.81 Billion ≈ $301.92 Million	-6.26pp
2008-12-31	7.98%	Skr205.83 Million ≈ $22.15 Million	Skr2.58 Billion ≈ $277.52 Million	-12.27pp
2007-12-31	20.25%	Skr394.57 Million ≈ $42.46 Million	Skr1.95 Billion ≈ $209.67 Million	-5.12pp
2006-12-31	25.38%	Skr527.21 Million ≈ $56.74 Million	Skr2.08 Billion ≈ $223.59 Million	--

pp = percentage points

About Swedish Orphan Biovitrum AB (publ)

ST:SOBI Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$18.16 Billion

Skr168.77 Billion SEK

Market Cap Rank

#1377 Global

#21 in Sweden

Share Price

Skr488.00

Change (1 day)

+2.05%

52-Week Range

Skr317.00 - Skr488.00

All Time High

Skr488.00